MOLECULAR MECHANISMS OF DRUG–RECEPTOR INTERACTIONS AND THEIR ROLE IN THERAPEUTIC RESPONSE
Keywords:
drug–receptor interaction; receptor pharmacology; affinity; efficacy; biased agonism; allosteric modulation; residence time; therapeutic response.Abstract
Drug–receptor interactions constitute the molecular starting point for many pharmacological effects, yet therapeutic response cannot be predicted from binding affinity alone. Receptors exist as dynamic conformational ensembles whose behavior is shaped by ligand structure, binding kinetics, efficacy, allosteric communication, receptor density, coupling efficiency, subcellular localization, desensitization, and downstream network context. This structured literature-based study synthesizes mechanistic principles that connect molecular recognition to clinically meaningful pharmacodynamics. Evidence from receptor theory, structural pharmacology, G protein-coupled receptor (GPCR) signaling, nuclear receptors, and kinetic pharmacology was integrated using an IMRAD framework. The analysis shows that orthosteric affinity determines the probability of target engagement, whereas efficacy and conformational selection determine how that engagement is converted into signaling. Partial agonism, inverse agonism, biased agonism, and allosteric modulation provide mechanistic explanations for drugs that bind the same receptor but produce different physiological outcomes. In addition, association and dissociation kinetics, especially drug–target residence time, can modify the magnitude and persistence of therapeutic effects independently of equilibrium affinity. These concepts help explain inter-drug differences in efficacy, safety, tolerance, tissue selectivity, and duration of action. Modern therapeutic optimization therefore requires an integrated view of affinity, kinetics, conformational dynamics, signaling bias, and biological context rather than a single-parameter model of receptor occupancy.
References
1.Black, J. W., & Leff, P. (1983). Operational models of pharmacological agonism. Proceedings of the Royal Society of London. Series B, Biological Sciences, 220(1219), 141–162. https://doi.org/10.1098/rspb.1983.0093
2.Kenakin, T., & Miller, L. J. (2010). Seven transmembrane receptors as shapeshifting proteins: The impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacological Reviews, 62(2), 265–304. https://doi.org/10.1124/pr.108.000992
3.Wootten, D., Christopoulos, A., Marti-Solano, M., Babu, M. M., & Sexton, P. M. (2018). Mechanisms of signalling and biased agonism in G protein-coupled receptors. Nature Reviews Molecular Cell Biology, 19, 638–653. https://doi.org/10.1038/s41580-018-0049-3
4.Changeux, J.-P., & Christopoulos, A. (2016). Allosteric modulation as a unifying mechanism for receptor function and regulation. Cell, 166(5), 1084–1102. https://doi.org/10.1016/j.cell.2016.08.015
5.Conn, P. J., Christopoulos, A., & Lindsley, C. W. (2009). Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders. Nature Reviews Drug Discovery, 8, 41–54. https://doi.org/10.1038/nrd2760
6.Urwyler, S. (2011). Allosteric modulation of family C G-protein-coupled receptors: From molecular insights to therapeutic perspectives. Pharmacological Reviews, 63(1), 59–126. https://doi.org/10.1124/pr.109.002501
7.Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006). Drug–target residence time and its implications for lead optimization. Nature Reviews Drug Discovery, 5, 730–739. https://doi.org/10.1038/nrd2082
8.Copeland, R. A. (2016). The drug–target residence time model: A 10-year retrospective. Nature Reviews Drug Discovery, 15, 87–95. https://doi.org/10.1038/nrd.2015.18
9.Knockenhauer, K. E., & Copeland, R. A. (2024). The importance of binding kinetics and drug–target residence time in pharmacology. British Journal of Pharmacology, 181(21), 4103–4116. https://doi.org/10.1111/bph.16104
10.Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A. A., Peters, J. A., Veale, E. L., et al. (2023). The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors. British Journal of Pharmacology, 180(Suppl 2), S23–S144. https://doi.org/10.1111/bph.16177
11.Gronemeyer, H., Gustafsson, J.-Å., & Laudet, V. (2004). Principles for modulation of the nuclear receptor superfamily. Nature Reviews Drug Discovery, 3, 950–964. https://doi.org/10.1038/nrd1551
12.Burris, T. P., Solt, L. A., Wang, Y., Crumbley, C., Banerjee, S., Griffett, K., Lundasen, T., Hughes, T., & Kojetin, D. J. (2013). Nuclear receptors and their selective pharmacologic modulators. Pharmacological Reviews, 65(2), 710–778. https://doi.org/10.1124/pr.112.006833
13.Imming, P., Sinning, C., & Meyer, A. (2006). Drugs, their targets and the nature and number of drug targets. Nature Reviews Drug Discovery, 5, 821–834. https://doi.org/10.1038/nrd2132
14.Liu, H., Zhong, H., & Guo, D. (2026). Understanding drug-target residence time and the implications on drug discovery. Expert Opinion on Drug Discovery, 21(2), 219–230. https://doi.org/10.1080/17460441.2026.2619070
15.Shao, Z., et al. (2025). Structural perspectives on biased allostery of GPCR signaling. Handbook of Experimental Pharmacology. Advance online publication. https://doi.org/10.1007/164_2025_767
